Stephen V. Liu, MD - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/WFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent unique, potent, and promising new options in the lung cancer treatment arsenal. Ongoing clinical trials evaluating ADCs, including those directed at trophoblast cell surface antigen 2 (TROP2), have demonstrated positive preliminary data in lung cancer, and additional results from other studies assessing monotherapy and rational combinatorial options are anticipated in the near future. As advances with TROP2-targeting ADCs continue, it is crucial for oncologists and other professionals involved in the care of patients with lung cancer to gain knowledge of the rationale, characteristics, efficacy, and different adverse event profiles of these novel therapies. They must also develop the necessary skills to enable rapid adoption of these therapies into their clinical practice should they receive regulatory approval. This educational activity, based on a recent live symposium, comprehensively analyzes the most recent evidence supporting the use of TROP2-targeting ADCs and combinations in lung cancer. In addition, practical guidance for effectively utilizing ADCs and recognizing and managing adverse events associated with these novel therapies is provided, along with perspectives on their potential impact within the lung cancer treatment arsenal. Upon completion of this activity, participants should be better able to: Describe the biology of TROP2, rationale for its therapeutic targeting, and the structure, characteristics, and mechanism of action of TROP2-targeting ADCs under investigation in lung cancer; Evaluate the different monotherapy or combinatorial treatment strategies with TROP2-targeting ADCs being investigated in first- and later-line settings in lung cancer, and available efficacy and safety data from these trials; and Integrate TROP2-targeting ADCs into treatment plans of appropriately selected patients with lung cancer in the context of clinical trials or clinical practice, if approved/available, considering the supporting evidence, expert recommendations, efficacy and safety profiles of the different agents, and patient needs and preferences.